Previous close | 1.0700 |
Open | 1.1000 |
Bid | 1.1100 x 1300 |
Ask | 1.1300 x 1200 |
Day's range | 0.9915 - 1.1400 |
52-week range | 0.2410 - 2.9300 |
Volume | |
Avg. volume | 1,947,919 |
Market cap | 207.877M |
Beta (5Y monthly) | 1.45 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.7690 |
Earnings date | 27 Feb 2023 - 03 Mar 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 1.63 |
Akebia Therapeutics ( NASDAQ:AKBA ) Third Quarter 2022 Results Key Financial Results Revenue: US$49.0m (flat on 3Q...
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -86.67% and 3.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 174.19% and 158.19%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?